A Randomized, Subject- and Investigator-blinded, Placebo-controlled Study to Assess the Efficacy and Safety of LOU064 in Patients With Inadequately Controlled Asthma
Latest Information Update: 16 Jun 2023
At a glance
- Drugs Remibrutinib (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 27 Apr 2023 Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 26 Jun 2020 Status changed from recruiting to discontinued.
- 13 Mar 2020 Planned End Date changed from 18 Jan 2021 to 6 Aug 2020.